Actively Recruiting
IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
Led by King's College London · Updated on 2025-03-05
113
Participants Needed
1
Research Sites
310 weeks
Total Duration
On this page
Sponsors
K
King's College London
Lead Sponsor
C
CHDI Foundation, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in participants' brains, ranging from several years before symptom onset to the advanced symptom stage. The study will be conducted over a three (3) year period (Baseline, Year-1, and Year-2).
CONDITIONS
Official Title
IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 21 to 75 years, male or female
- Adequate vision and hearing to complete psychological tests
- Able to give informed consent
- Willing to use effective contraception (for Cohort 2)
- Vital signs within specified ranges
- Generally in good health without significant diseases
- Physically and psychologically able to travel to study centers in London, UK
- For PwHD without symptoms: Huntington's disease gene expansion with e40 CAG repeats and specific clinical scores
- For PwHD with early symptoms: Huntington's disease gene expansion with e40 CAG repeats and defined clinical criteria
- For PwHD with late symptoms: Huntington's disease gene expansion with e40 CAG repeats and defined clinical criteria
- Healthy controls matched in age and sex, with no genetic risk for HD
You will not qualify if you...
- History or presence of other neurological disorders affecting brain imaging or examination
- Primary psychiatric disorders unrelated to Huntington's disease
- Use of medications affecting PET target receptors
- Pregnancy or breastfeeding
- Contraindications to MRI such as metal implants or fragments
- History of alcoholism or substance abuse within 3 years
- Positive drug screen for substances of abuse
- History of cancer
- Claustrophobia
- Severe back pain preventing prolonged scanning
- Contraindication for arterial cannulation (Cohort 2 only)
- Inability to communicate or cooperate with study team
- Participation in clinical trials with therapies targeting PET receptors within 3 months
- Any condition interfering with safety or tolerability assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
King's College London
London, England, United Kingdom, SE5 8AF
Actively Recruiting
Research Team
S
Steve Williams, PhD
CONTACT
D
Daniel J van Wamelen, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here